Navtemadlin (KRT-232)
Myelofibrosis (in combination with ruxolitinib)
Key Facts
About Kartos Therapeutics
Kartos Therapeutics is a private, clinical-stage biotech advancing navtemadlin, a potent and selective oral MDM2 inhibitor, for cancers with wild-type TP53. The company's lead program is in advanced clinical development for myelofibrosis, with additional studies in acute myeloid leukemia and Merkel cell carcinoma. Kartos's strategy centers on leveraging deep biological insight into the MDM2-p53 pathway to induce apoptosis in cancer cells, targeting significant unmet needs in both hematologic malignancies and solid tumors.
View full company profileAbout Kartos Therapeutics
Kartos Therapeutics is a private, clinical-stage biotech advancing navtemadlin, a potent and selective oral MDM2 inhibitor, for cancers with wild-type TP53. The company's lead program is in advanced clinical development for myelofibrosis, with additional studies in acute myeloid leukemia and Merkel cell carcinoma. Kartos's strategy centers on leveraging deep biological insight into the MDM2-p53 pathway to induce apoptosis in cancer cells, targeting significant unmet needs in both hematologic malignancies and solid tumors.
View full company profileAbout Kartos Therapeutics
Kartos Therapeutics is a private, clinical-stage biotech advancing navtemadlin, a potent and selective oral MDM2 inhibitor, for cancers with wild-type TP53. The company's lead program is in advanced clinical development for myelofibrosis, with additional studies in acute myeloid leukemia and Merkel cell carcinoma. Kartos's strategy centers on leveraging deep biological insight into the MDM2-p53 pathway to induce apoptosis in cancer cells, targeting significant unmet needs in both hematologic malignancies and solid tumors.
View full company profileAbout Kartos Therapeutics
Kartos Therapeutics is a private, clinical-stage biotech advancing navtemadlin, a potent and selective oral MDM2 inhibitor, for cancers with wild-type TP53. The company's lead program is in advanced clinical development for myelofibrosis, with additional studies in acute myeloid leukemia and Merkel cell carcinoma. Kartos's strategy centers on leveraging deep biological insight into the MDM2-p53 pathway to induce apoptosis in cancer cells, targeting significant unmet needs in both hematologic malignancies and solid tumors.
View full company profile